(NASDAQ: NVAX) Novavax's forecast annual revenue growth rate of -34.37% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.67%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.46%.
Novavax's revenue in 2026 is $1,123,479,000.On average, 11 Wall Street analysts forecast NVAX's revenue for 2026 to be $67,955,694,581, with the lowest NVAX revenue forecast at $39,999,145,138, and the highest NVAX revenue forecast at $90,760,209,443. On average, 10 Wall Street analysts forecast NVAX's revenue for 2027 to be $45,229,388,973, with the lowest NVAX revenue forecast at $17,564,494,871, and the highest NVAX revenue forecast at $74,072,309,956.
In 2028, NVAX is forecast to generate $59,196,258,178 in revenue, with the lowest revenue forecast at $42,698,993,747 and the highest revenue forecast at $73,013,226,314.